How Can We Help?
Skip to content
Researcher looking at a book

Apr. 20 Webinar: An Overview of Non CYP-Mediated Metabolism Pathways and In Vitro Evaluation Strategies

  • Published on March 20, 2021
  • Drug Metabolism
  • Non-CYP Enzymes
  • Webinars

Presenter: Brian Ogilvie, Ph.D, Vice President of Scientific Consulting at SEKISUI XenoTech

Abstract:

Although cytochrome P450 (CYP)-mediated metabolism continues to be of major importance for a large proportion of small molecule new drug candidates, various methods in recent decades have accelerated the development of drug candidates with significant non CYP-mediated metabolism. Increased interest in these molecules stems from the efforts to develop drug candidates possibly lacking CYP metabolism liability from the drug interactions and toxicity standpoints. Regulatory agencies still have a safety interest in understanding the biochemical pathways involved in the metabolism of these drugs.

In general, uridine diphosphate glucuronosyltransferases (UGTs) are the most common enzymes involved in metabolism after CYP enzymes, followed by numerous hydrolases, carbonyl reductases, aldehyde oxidase and other enzymes. Reaction phenotyping of many of these enzymes is not as straightforward as with CYPs due to their inherent diversity and limited research tools available. With UGTs, commercially available recombinant human preparations are available for the most relevant enzymes, although selective inhibitors may be lacking. In the case of aldehyde oxidase, a recombinant human enzyme and relatively selective inhibitors are available. For hydrolases, carbonyl reductases and other enzymes such as FMO, strategies may rely on the use of various subcellular fractions, plasma, and inhibitors to elucidate a plurality of the enzymes that may contribute to drug metabolism. The complexity of elucidation of non CYP-mediated metabolism is reflected in regulatory safety requirements.

In this webinar, Dr. Brian Ogilvie will discuss strategies to address non-CYP related metabolism questions in your drug’s safety assessment and following the presentation, he will answer follow up questions from the audience.

Key concepts discussed in this webinar will include:

  • In vitro approaches to evaluate non-CYP enzyme contribution to new drug candidates
  • Case examples

Register for the Live Webinar on April 20th at:
9am EDT / 16:00 CEST
or 2pm EDT / 11am PDT
or Register to Only Watch On-Demand After the Event

(all live event as well as on-demand registrants will receive a copy of the slides and a link to the recording a few days after the event)

About the Presenter:

Dr. Brian Ogilvie currently serves as Vice President of Scientific Consulting at SEKISUI XenoTech. Brian obtained his Ph.D. in toxicology from the University of Kansas Medical Center and B.A. in molecular biology from William Jewell College. He joined XenoTech in 1997. From 1999 to 2006 Dr. Ogilvie was the head of the CYP Inhibition Department at SEKISUI XenoTech. Brian is an author or coauthor on over 50 scientific posters, peer-reviewed publications and book chapters on the topics of drug metabolism, transport and drug-drug interactions, and has represented the company as an invited speaker at various drug metabolism conferences. In April 2006, Brian became a member of the SEKISUI XenoTech Consulting Department, in which he participates in drug-drug interaction-related R&D projects and authoring various publications, and also writes expert opinions for consulting clients. As Vice President of Scientific Consulting, Dr. Ogilvie is additionally involved in quality management and strategic planning for the company in scientifically relevant areas.

What topic would you like to hear about?

Our experts are constantly on the hunt for new and exciting topics to present on, and nothing helps us figure out what you want to hear more than requests and feedback! Use our form to submit your request so we can continue producing educational materials you look forward to

Access ADME